Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
964.2 USD | -0.21% | -0.26% | +9.93% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 25 | Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.93% | 104B | |
+3.12% | 108B | |
+6.38% | 23.66B | |
-11.79% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.04% | 16.19B | |
+4.52% | 13.72B | |
+34.85% | 12.22B | |
-5.90% | 10.36B |
- Stock
- Equities
- Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals's COVID-19 Drug Reduces Infection Risk by 82% in Late-Stage Study